Clinical trial
Identification of Novel Predictive Factors and Their Significance for Improving Radioligand Therapy Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT07863986 is registered in ClinicalTrials.gov with Lithuanian University of Health Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Identification of Novel Predictive Factors and Their Significance for Improving Radioligand Therapy Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
- Lead sponsor
- Lithuanian University of Health Sciences
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- August 4, 2026
- Completion date
- August 31, 2031
- Enrollment
- 70 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
neoplasm metastases, prostate cancer, prostatic neoplasms, prostatic neoplasms, castration-resistant